Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionHeartflow Inc. Common Stock (HTFL)
Fair value
Not available
ACCE price target
$40.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $56.71 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
55
out of 100
Analysts
80% buy
10 covering
P/E
0.0x
forward 0.0x
1-year return
+42.1%
Dividend yield
0.00%
Heartflow Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Heartflow sells AI-driven cardiac imaging software, including its FFRct and plaque analysis products, which turn standard CT scans into non-invasive estimates of blood flow and coronary disease. Its 80.1% gross margin reflects the software economics, and revenue growth of 47.6% shows demand is compounding faster than most of healthcare. The company is still loss-making, with an operating margin of -27.9% and a return on equity of -154.2%, so the investment case rests on operating leverage arriving before the cash runs short. At a $4.4B market cap with no index membership yet, the stock is a candidate for a deeper look, with the reimbursement trajectory and the path to positive operating margin as the questions to resolve.